UNSPSC 51122807: Sotalol

This classification denotes a cation channel blocker and adrenergic antagonist with the molecular formula C12H20N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) A6D97U294I, chemically known as methanesulfonanilide, 4-(1-hydroxy-2-(isopropylamino)ethyl)- but more generally known as sotalol, which bears US NIH Compound Identifier 5253. European Medicines Agency schedules Sotalol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10607MIG.

UNSPSC 51122807 Sotalol, a Commodity code, covers emergency and maintenance pharmaceuticals—specifically injectable cardiac and hemodynamic medications—that state and local governments procure for emergency medical services, hospital systems, and public health programs. State and local buyers under this code source individual medication line items through direct sealed-bid procurements, cooperative purchasing agreements, and request-for-information market surveys. Issuing bodies span city fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances serving participating state and local facilities. The work being solicited includes supplying specific medication units with firm pricing, delivery within defined timelines, warranty periods covering defects and expiration-date management, and compliance with FDA standards, Good Manufacturing Practices, and OSHA hazard communication requirements.

Recent activity spans Florida, Texas, and Minnesota-led multistate consortia. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) in April 2026 for Advanced Life Support Medications including labetalol, epinephrine, adenosine, and diltiazem for Tampa Fire Rescue, with an estimated contract value of $40,000.00 and a response deadline of April 8, 2026; the solicitation included a 5 percent Small Local Business Enterprise bid discount. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and awarded vendors effective July 1, 2026. The Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription programs and vendor capabilities for future formal procurement. Cooperative purchasing and state-level set-asides are active mechanisms; delivery, expiration-date warranty, and EDI capability are standard performance requirements.